Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-1995 | 12-1994 | 12-1993 | 12-1992 | 12-1991 | |
| Sales | 6,763,800 | 5,711,600 | 6,452,400 | 6,167,300 | 5,725,700 |
| Cost of Goods | 1,885,700 | 1,679,700 | 1,959,000 | 1,897,000 | 1,717,700 |
| Gross Profit | 4,878,100 | 4,031,900 | 4,493,400 | 4,270,300 | 4,071,500 |
| Operating Expenses | 2,897,000 | 2,237,700 | 2,668,100 | 2,549,100 | 2,240,400 |
| Operating Income | 1,981,800 | 1,794,900 | 1,825,300 | 1,721,200 | 1,768,300 |
| Interest Expense | 286,300 | 103,800 | 0 | 0 | 0 |
| Other Income | 70,100 | 7,500 | -1,123,400 | -538,900 | 110,900 |
| Pre-tax Income | 1,765,600 | 1,698,600 | 701,900 | 1,182,300 | 1,879,200 |
| Income Tax | 459,000 | 513,500 | 210,800 | 354,700 | 564,500 |
| Net Income Continuous | 1,306,600 | 1,398,000 | 1,347,100 | 1,223,595 | 1,314,700 |
| Net Income Discontinuous | 984,300 | 0 | -10,900 | -118,900 | 0 |
| Net Income | $2,290,900 | $1,286,100 | $480,200 | $708,700 | $1,314,700 |
| EPS Basic Total Ops | 2.02 | 1.11 | 0.41 | 0.61 | 1.12 |
| EPS Basic Continuous Ops | 1.15 | 1.21 | 1.15 | 1.05 | 1.12 |
| EPS Basic Discontinuous Ops | 0.86 | N/A | -0.01 | -0.10 | N/A |
| EPS Diluted Total Ops | 2.02 | 1.11 | 0.41 | 0.61 | 1.12 |
| EPS Diluted Continuous Ops | 1.15 | 1.21 | 1.15 | 1.05 | 1.12 |
| EPS Diluted Discontinuous Ops | 0.86 | N/A | -0.01 | -0.10 | N/A |
| EBITDA(a) | $2,535,500 | $2,227,100 | $2,223,600 | $2,089,300 | $2,067,800 |